Search

everythinglearnresearchcommunity

for

Search:↓

Pantethine may boost the immune system's ability to fight sarcoma.

Studying premature aging syndromes helps understand human aging and suggests potential treatments.

Systemic treatments like hydroxychloroquine and cyclosporine A help with Lichen Planopilaris and Frontal Fibrosing Alopecia, but ongoing treatment is needed.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Inhibiting ODC can prevent UV-induced skin cancer.

LPA3 signaling in the uterus is crucial for placental formation and fetal development.

Eupafolin nanoparticles help protect skin cells from damage caused by air pollution.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

Leptin-deficient mice, used as a model for Type 2 Diabetes, have delayed wound healing due to impaired contraction and other dysfunctional cellular responses.

Prostaglandins and the enzyme AKR1C3 could play a role in skin cancer and hair loss, and further research is needed to understand these mechanisms.

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Combination pharmacotherapy is generally more effective for treating keloids and hypertrophic scars.

Effective treatment guidelines for frontal fibrosing alopecia are still unclear.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

Antiandrogen therapy helps treat genetic hair loss.

The conclusion is that more hair loss (androgenetic alopecia) is linked to larger prostate size, suggesting hair loss could be an early sign of benign prostatic hyperplasia.

Gender-affirming therapy can cause skin issues like acne and hair loss in transgender adolescents, and more research is needed on its dermatological effects.

New understanding and treatments for hair loss are improving, but more research is needed.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

GRHL3 is important for controlling gene activity in skin cells during different stages of their development.

Certain microRNAs may help treat alopecia areata by targeting immune pathways.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.